A typical transition timeline might look like this: Weeks 1-4: Start tirzepatide 2.5 mg weekly while maintaining phentermine at current dose Weeks 5-8: Increase tirzepatide to 5 mg weekly, reduce phentermine to 15 mg daily (if currently on a higher dose) Weeks 9-12: Increase tirzepatide to 7.5 mg weekly, begin tapering phentermine to every other day Week 13+: Discontinue phentermine, continue tirzepatide titration as needed This is a general framework, not a prescription
Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
This broader push for sustainability is shaping Technology Transfer and CapEx planning as well new sites are being built to LEED/energy standards, and R&D into green peptide synthesis is increasingly financed
Mounjaro may indirectly cause fatigue due to calorie restriction, low blood sugar, or stomach-related side effects
The reduction in ethanol intake provides a therapeutic rationale for the use of GLP-1R agonists in ALD
Millions of patients have used them to lose significant weight
